FGFR2 fusions occur in up to 14% of patients with intrahepatic cholangiocarcinoma (iCCA) and have been considered as therapeutic target for FGFR inhibitors (FGFRi). Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.